GlassScriptPhysician profile
Ali R Afshar
NPI 1083901177
$2,456.12
in general payments reported to CMS, 2019-2025
37 companies · $78.50 in 2025
The $78.50 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $265 · 2021: $225 · 2022: $430 · 2023: $540 · 2024: $331 · 2025: $78.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $356.74 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $276.33 | 2019-2023 | Wegovy |
| Abbott Laboratories | $215.92 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $182.96 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $181.82 | 2019-2022 | |
| Amgen INC. | $133.37 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $118.52 | 2019-2023 | Gardasil 9, Vaxneuvance |
| Endo USA, INC. | $102.40 | 2024-2025 | Xiaflex, Aveed |
| Aadi Bioscience, INC. | $87.87 | 2024 | Fyarro |
| Lilly USA, LLC | $77.83 | 2019-2023 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $74.60 | 2019-2022 | |
| Allergan, INC. | $62.76 | 2019 | |
| Axonics, INC. | $47.43 | 2024 | Axonics |
| Boston Scientific Corporation | $46.32 | 2019 | |
| Janssen Biotech, INC. | $43.76 | 2023-2024 | Erleada |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $36.85 | 2021-2024 | Euflexxa |
| Dexcom, INC. | $34.24 | 2022-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $33.24 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $25.74 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $25.09 | 2019-2023 | Xarelto |
| Abbvie INC. | $23.86 | 2022 | |
| Nevro Corp. | $22.51 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.62 | 2023 | Quviviq |
| Exact Sciences Corporation | $20.25 | 2023 | Cologuard Collection Kit |
| Biotissue Holdings INC. | $20.25 | 2022 | |
| Masimo Corporation | $19.57 | 2021 | |
| Sanofi Pasteur INC. | $17.79 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.78 | 2019 | |
| Lundbeck LLC | $16.06 | 2023 | Rexulti |
| Hologic Sales and Service, LLC | $15.90 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.00 | 2020 | |
| Circassia INC. | $14.92 | 2020 | |
| Melinta Therapeutics, LLC | $14.71 | 2019 | |
| Phadia US INC. | $14.19 | 2019 | |
| 180 Medical, INC. | $13.25 | 2024 | |
| Tolmar, INC. | $13.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Afshar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.